Vaxart re­verse merges its way on­to Nas­daq, climb­ing aboard the Avi­ra­gen shell

Vaxart says it’s about to un­veil pos­i­tive re­sults from an ear­ly-stage study of a new vac­cine, and it’s cel­e­brat­ing with a re­verse merg­er on­to Nas­daq …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.